Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder

Human Psychopharmacology

Volumn 28, Issue 3, 2013, Pages 258-262

  Cooper, Alissa J ^a   Rickels, Karl ^a   Lohoff, Falk W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

anxiety disorders; depression; opioid receptor; pharmacogenetics; treatment response

Indexed keywords

MU OPIATE RECEPTOR; MU OPIATE RECEPTOR OPRM1; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EUROPEAN AMERICAN; FEMALE; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANXIETY DISORDERS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84878221867     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2317     Document Type: Article

References (37)

1. Andrews G, Sanderson K, Slade T, Issakidis C,. 2000. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bull World Health Organ 78: 446-454.
2. Arntz A, Merckelbach H, de Jong P,. 1993. Opioid antagonist affects behavioral effects of exposure in vivo. J Consult Clin Psychol 61: 865-870.
3. Baldwin DS, Nair RV,. 2005. Escitalopram in the treatment of generalized anxiety disorder. Expert Rev Neurother 5: 443-449.
4. Bond C, Laforge KS, Tian M, et al,. 1998. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95: 9608-9613.
5. Bowers ME, Choi DC, Ressler KJ,. 2012. Neuropeptide regulation of fear and anxiety: implications of cholecystokinin, endogenous opioids, and neuropeptide Y. Physiol Behav 107: 699-710.
6. Egan KJ, Carr JE, Hunt DD, Adamson R,. 1988. Endogenous opiate system and systematic desensitization. J Consult Clin Psychol 56: 287-291.
7. Fanselow MS, Kim JJ, Young SL, et al,. 1991. Differential effects of selective opioid peptide antagonists on the acquisition of pavlovian fear conditioning. Peptides 12: 1033-1037.
8. Fatseas M, Denis C, Lavie E, Auriacombe M,. 2010. Relationship between anxiety disorders and opiate dependence-a systematic review of the literature: implications for diagnosis and treatment. J Subst Abuse Treat 38: 220-230.
9. Filliol D, Ghozland S, Chluba J, et al,. 2000. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25: 195-200.
10. Garriock HA, Tanowitz M, Kraft JB, et al,. 2010. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry 167: 565-573.
11. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E,. 2000. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283: 3082-3088.
12. Gorwood P,. 2004. Generalized anxiety disorder and major depressive disorder comorbidity: an example of genetic pleiotropy? Eur Psychiatry 19: 27-33.
13. Horstmann S, Lucae S, Menke A, et al,. 2010. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35: 727-740.
14. Jorm AF, Prior M, Sanson A, et al,. 2002. Lack of association of a single-nucleotide polymorphism of the mu-opioid receptor gene with anxiety-related traits: results from a cross-sectional study of adults and a longitudinal study of children. Am J Med Genet 114: 659-664.
15. Kasai S, Ikeda K,. 2011. Pharmacogenomics of the human micro-opioid receptor. Pharmacogenomics 12: 1305-1320.
16. Kennedy SE, Koeppe RA, Young EA, Zubieta JK,. 2006. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 63: 1199-1208.
17. Lohoff FW, Aquino TD, Narasimhan S, Multani PK, Etemad B, Rickels K,. 2011. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 13: 21-26.
18. Lohoff FW, Narasimhan S, Rickels K,. 2012. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. DOI: 10.1038/tpj.2012.33.
19. Lucae S, Ising M, Horstmann S, et al,. 2010. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol 20: 65-68.
20. Mague SD, Blendy JA,. 2010. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 108: 172-182.
21. Mcmahon FJ, Buervenich S, Charney D, et al,. 2006. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78: 804-814.
22. Mcnally GP, Westbrook RF,. 2003. Opioid receptors regulate the extinction of Pavlovian fear conditioning. Behav Neurosci 117: 1292-1301.
23. Narasimhan S, Lohoff FW,. 2012. Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. Pharmacogenomics 13: 441-464.
24. Narasimhan S, Aquino TD, Hodge R, Rickels K, Lohoff FW,. 2011. Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Neurosci Lett 503: 200-202.
25. Narasimhan S, Aquino TD, Multani PK, Rickels K, Lohoff FW,. 2012. Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res 198: 112-115.
26. Pasche S,. 2012. Exploring the comorbidity of anxiety and substance use disorders. Curr Psychiatry Rep 14: 176-181.
27. Peters EJ, Slager SL, Jenkins GD, et al,. 2009. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 19: 1-10.
28. Pollack MH,. 2009. Refractory generalized anxiety disorder. J Clin Psychiatry 70 (Suppl 2): 32-38.
29. Reinhold JA, Mandos LA, Rickels K, Lohoff FW,. 2011. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother 12: 2457-2467.
30. Ribeiro SC, Kennedy SE, Smith YR, Stohler CS, Zubieta JK,. 2005. Interface of physical and emotional stress regulation through the endogenous opioid system and mu-opioid receptors. Prog Neuropsychopharmacol Biol Psychiatry 29: 1264-1280.
31. Rickels K, Downing R, Schweizer E, Hassman H,. 1993. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50: 884-895.
32. Rickels K, Rynn M, Iyengar M, Duff D,. 2006. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 67: 41-47.
33. Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ,. 2010. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry 67: 1274-1281.
34. Rickels K, Rynn M,. 2002. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 63: (Suppl 14): 9-16.
35. Samaco RC, Mandel-Brehm C, Mcgraw CM, Shaw CA, Mcgill BE, Zoghbi HY,. 2012. Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome. Nat Genet 44: 206-211.
36. Sery O, Prikryl R, Castulik L, St'Astny F,. 2010. A118G polymorphism of OPRM1 gene is associated with schizophrenia. J Mol Neurosci 41: 219-222.
37. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W,. 2005. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280: 32618-32624.